52 articles in this category
Groundbreaking research reveals a 44-metabolite blood signature that predicts type 2 diabetes risk with unprecedented accuracy, potentially transforming preventive healthcare and early intervention strategies.
Groundbreaking research from Liverpool reveals that metformin, a common diabetes medication, may reduce age-related macular degeneration by 37%, offering new hope for preserving eyesight in aging populations.
Arecor Therapeutics announces strategic plans to advance its innovative insulin therapy into Phase II clinical trials by 2026, following successful 2025 developments that position the company at the forefront of diabetes treatment innovation.
Encellin's Phase 1 clinical trial reveals groundbreaking results for encapsulated islet therapy in type 1 diabetes patients, demonstrating no fibrosis and opening new possibilities for cell-based treatments.
